The effect of fluvastatin on plasma adiponectin levels in dyslipidaemia
- 12 April 2006
- journal article
- Published by Wiley in Clinical Endocrinology
- Vol. 64 (5) , 567-572
- https://doi.org/10.1111/j.1365-2265.2006.02510.x
Abstract
Objective There is controversy about the effects of statins on insulin resistance and plasma adiponectin. The aim of this study was to investigate the effects of fluvastatin treatment on these parameters in a group of dyslipidaemic patients who had no confounding factors for insulin resistance or alterations in plasma adiponectin. Design and patients Forty‐nine patients [27 males, 22 females; mean age 47·2 ± 10·3 years; body mass index (BMI) 29·64 ± 3·2 kg/m2] with dyslipidaemia and 20 controls (six males, 14 females; mean age 45·3 ± 9·31 years; BMI 30·07 ± 4·04 kg/m2) were enrolled. All patients were treated initially with therapeutic lifestyle changes (TLC) for 6 weeks. Six out of 49 subjects were excluded from the study. Then, 24 out of 43 patients with high blood cholesterol despite TLC were allocated to fluvastatin 80 mg daily plus TLC, and the remaining 19 patients with normal cholesterol were subjected to TLC alone for additional 12 weeks. Measurements Plasma adiponectin, immunoreactive insulin levels, BMI, waist circumference, blood pressure, lipids, and glucose were determined. The insulin sensitivity index was quantified using the homeostasis model assessment (HOMA). Results TLC caused significant improvement in plasma insulin (P = 0·02) and elevation in plasma adiponectin (P = 0·02). Fluvastatin treatment decreased total cholesterol and low density lipoprotein (LDL)‐cholesterol significantly (P = 0·01 and P = 0·02, respectively). No significant effect of fluvastatin was observed on plasma insulin or adiponectin or on the HOMA index. Conclusions Fluvastatin does not improve plasma adiponectin levels and insulin sensitivity, despite its beneficial effects on lipid levels. Our data, however, were limited by the fact that a more accurate method of assessing insulin sensitivity, the euglycaemic–hyperinsulinaemic glucose clamp technique, was not used.Keywords
This publication has 39 references indexed in Scilit:
- Effects of Statins on 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Beyond Low-Density Lipoprotein CholesterolThe American Journal of Cardiology, 2005
- Vascular and Metabolic Effects of Combined Therapy With Ramipril and Simvastatin in Patients With Type 2 DiabetesHypertension, 2005
- Additive Beneficial Effects of Losartan Combined With Simvastatin in the Treatment of Hypercholesterolemic, Hypertensive PatientsCirculation, 2004
- Anti-inflammatory Properties of StatinsSeminars in Vascular Medicine, 2004
- Pitavastatin Inhibits Vascular Smooth Muscle Cell Proliferation by Inactivating Extracellular Signal-Regulated Kinases 1/2.Journal of Atherosclerosis and Thrombosis, 2003
- Disruption of Adiponectin Causes Insulin Resistance and Neointimal FormationJournal of Biological Chemistry, 2002
- Effects of Fluvastatin Treatment on Insulin Sensitivity in Patients with HyperlipidaemiaJournal of International Medical Research, 2002
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Inhibition by simvastatin, but not pravastatin, of glucose‐induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L‐type Ca2+ channels in rat islet β‐cellsBritish Journal of Pharmacology, 1999
- cDNA Cloning and Expression of a Novel Adipose Specific Collagen-like Factor, apM1 (AdiposeMost Abundant Gene Transcript 1)Biochemical and Biophysical Research Communications, 1996